Stock Screener App

무료 -

설치하다

73.40

4.42% -3.69

Cytokinetics Inc (CYTK)

개요 뉴스 가격 이력 옵션 체인 Financials CYTK 왜 하락? 토론 예측 주식 분할

Cytokinetics Inc 주식(CYTK)의 최신 뉴스

Truist raises Cytokinetics stock price target on positive trial data - Investing.com

Fresh off big clinical trial win, Cytokinetics looks to raise about $650 million - The Business Journals

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2026 Earnings Call Transcript - Insider Monkey

RBC Adds Speculative Risk to Outperform Rating on Cytokinetics, Lifts Price Target to $119 From $101 - marketscreener.com

RBC Capital raises Cytokinetics stock price target on strong launch - Investing.com

RBC Capital raises Cytokinetics stock price target on strong launch By Investing.com - Investing.com Australia

Cytokinetics stock hits 52-week high at 74.35 USD By Investing.com - Investing.com Canada

Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge By Investing.com - Investing.com Nigeria

Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000% - Yahoo Finance

5 Stocks Turning Heads With Double-Digit Gains - Insider Monkey

Cytokinetics Q1 Earnings Call Highlights - Yahoo Finance

Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge - Investing.com UK

Insider Sell Alert: Andrew Callos Sells Shares of Cytokinetics I - GuruFocus

Cytokinetics EVP Malik sells $270,795 in company stock By Investing.com - Investing.com Canada

Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial - Yahoo Finance

Cytokinetics Q1 2026 Earnings Call Transcript - MarketBeat

Cytokinetics EVP Malik sells $270,795 in company stock - Investing.com

Cytokinetics (CYTK) Q1 2026 Earnings Transcript - AOL.com

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore

Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing - marketscreener.com

Cytokinetics announces proposed public offering of common stock - marketscreener.com

Cytokinetics (CYTK) EVP executes 3,500-share option exercise and sale - Stock Titan

Cytokinetics metrics satisfy in nHCM phase III - BioWorld News

Cytokinetics Incoffers common stock with aggregate public offering price of $650 millionSEC filing - marketscreener.com

Cytokinetics Q1 Loss Widens, Revenue Rises - marketscreener.com

Earnings Flash (CYTK) Cytokinetics Posts Q1 Loss $1.67, vs. FactSet Est of $1.65 Loss - marketscreener.com

Cytokinetics plans $650 million common stock offering - Investing.com

Cytokinetics plans $650M stock offering - MSN

Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q1 Revenue $19.4M, vs. FactSet Est of $8.5M - marketscreener.com

Cytokinetics (NASDAQ: CYTK) seeks $650M via common stock shelf offering - Stock Titan

Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline - TipRanks

[144] CYTOKINETICS INC SEC Filing - Stock Titan

Cytokinetics: Q1 Earnings Snapshot - marketscreener.com

Insider to sell 23,906 Common shares — Cytokinetics (NASDAQ: CYTK) - Stock Titan

Cytokinetics plans $650 million common stock offering By Investing.com - Investing.com Canada

Cytokinetics Announces Proposed Public Offering of Common Stock - The Manila Times

Director Wierenga trims Cytokinetics (CYTK) stake via option exercise and sale - Stock Titan

How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - Investor's Business Daily

Cytokinetics (CYTK) CFO trims stake with 23,906-share sale - Stock Titan

Biotech Cytokinetics seeks $650M stock sale, plus 15% option - Stock Titan

Cytokinetics stock adds more than $1 billion of valuation in a single day — Here's why - The Business Journals

BofA raises Cytokinetics price target on ACACIA trial results By Investing.com - Investing.com Australia

[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan

Cytokinetics (NASDAQ: CYTK) details MYQORZO rollout and $1.1B cash - Stock Titan

Cytokinetics (CYTK) EVP Callos exercises options and sells 11,333 shares - Stock Titan

[10-Q] CYTOKINETICS INC Quarterly Earnings Report - Stock Titan

MYQORZO launch drives revenue jump as Cytokinetics (NASDAQ: CYTK) posts Q1 2026 loss - Stock Titan

680 patients prescribed MYQORZO in Q1; EU approval follows - Stock Titan

BofA raises Cytokinetics price target on ACACIA trial results - Investing.com

Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $102 - 富途牛牛

MSN Money - MSN

Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia

Cytokinetics earnings on deck as trial results loom large - Investing.com

CYTK Stock Jumps As Traders Brace For ACACIA Data - StocksToTrade

Why Cytokinetics Stock Is Surging After Trial Win - TipRanks

Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial - FirstWord Pharma

Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Announces Target Price $106 - Moomoo

Cytokinetics stock hits 52-week high after ACACIA-HCM trial - Yahoo Finance

Can Myqorzo drive growth for Cytokinetics amid competition? - MSN

Cytokinetics Announces Positive Topline Results from ACACIA-HCM - The National Law Review

Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Benzinga

Cytokinetics stock hits 52-week high after heart drug passes expanded Phase 3 trial - qz.com

Are analysts too quick to gloss over Lilly’s liver case? - statnews.com

This Is Why Cytokinetics Stock (CYTK) Soared Today - TipRanks

CYTK Jumps As $95 Target, Trial Catalyst Ignite Trading - StocksToTrade

After rival fails, Cytokinetics could broaden Myqorzo label - pharmaphorum

Cytokinetics stock hits 52-week high at 74.35 USD - Investing.com

Cytokinetics heart drug scores in closely watched trial - BioPharma Dive

ROIV

$28.50

0.78%

RPRX

$50.76

2.57%

BNTX

$92.69

3.01%

INSM

$138.73

1.11%

RVMD

$147.88

0.02%

ONC

$305.60

2.86%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개